Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Merck & Co., Inc. (NYSE:MRK) continues to find success with its product pipeline, with another of its treatment options receiving FDA approval.
Merck announced Wednesday that the FDA OK'd RECARBIO, a combination of imipenem, cilastatin and relebactam in a 1.25g injection formulation.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The drug is intended to treat patients 18 and older for complicated urinary tract infection, or cUTI — including pyelonephritis — caused by some susceptible gram-negative microorganisms and for which there is limited or no alternative treatment options.
The antibacterial medication is also indicated to treat complicated intra-abdominal infections.
"RECARBRIO offers an additional treatment option for patients with cIAI and cUTI who have limited and, in some cases, no alternative therapeutic options," Keith Kaye, a principal investigator of the clinical program that evaluated the antibiotic combo, said in a statement.
Merck shares were trading higher by 0.42% at $81.93 at the time of publication Wednesday.
Related Links:
Merck Strikes $773M Deal For Privately Held Tilos Therapeutics
Washington Worries Trigger Bearish Merck Options Trades
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.